Business context and reporting period
Vir Biotechnology, Inc. reported an executive appointment on October 1, 2026. Aziz Sawaf is appointed Executive Vice President and Chief Financial Officer, effective October 5, 2026, and will serve as principal financial officer. Interim principal financial officer Brent Sabatini will continue as Senior Vice President and Chief Accounting Officer and principal accounting officer.
Financial and compensation details
- Annualized base salary: $520,000; target annual bonus: 45% of salary, or $234,000 at the stated base salary.
- One-time cash sign-on bonus: $150,000, split equally between payment on or around the effective date and payment after the first anniversary, subject to continued employment.
- Planned equity awards around November 15, 2026: an option for 150,000 shares, with an exercise price equal to fair market value on the grant date, and 75,000 restricted stock units. Both awards vest over four years, subject to continued employment.
- For a covered termination within 12 months after a change in control: 12 months of base salary plus target cash bonus, up to 12 months of continued health benefits, and full acceleration of outstanding equity awards. For a covered termination outside that period: nine months of base salary plus a prorated target bonus and up to nine months of continued health benefits.
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating performance figures.
Material changes and outlook
The principal change is the appointment of a permanent CFO, replacing the interim principal financial officer. The filing contains no financial guidance, operating outlook, or management commentary on business performance. The company stated that it expects to file Sawaf’s offer letter with its Form 10-Q for the quarter ended September 30, 2026.
Key facts for investors to verify
- Confirm the appointment’s effective date and the CFO/principal financial officer transition.
- Review the offer letter when filed, including the compensation and equity award terms.
- Check the eventual equity grant date, share price used to set the option exercise price, and award vesting details.
- Note that the disclosed compensation and severance arrangements are not accompanied by financial performance or liquidity data in this filing.